



































Objectives	 To	 validate	 the	 educational	 needs	 assessment	 tool	 (The	 ENAT)	 as	 a	 generic	 tool	 for	
assessing	the	educational	needs	of	patients	with	rheumatic	diseases	in	European	Countries.	
Methods	A	convenience	sample	of	patients	from	seven	European	countries	was	included,	comprising	
the	 following	 diagnostic	 groups:	 ankylosing	 spondylitis	 (AS),	 psoriatic	 arthritis	 (PsA),	 systemic	
sclerosis	 (SSc),	 systemic	 lupus	 erythematosus	 (SLE),	 osteoarthritis	 (OA)	 and	 fibromyalgia	 syndrome	
(FMS).	 Translated	 versions	 of	 the	 ENAT	 were	 completed	 through	 surveys	 in	 each	 country.	 Rasch	
analysis	was	used	 to	 assess	 the	 construct	 validity	of	 the	 adapted	ENATs	 including	differential	 item	
functioning	by	culture	(cross-cultural	DIF).	Initially,	the	data	from	each	country	and	diagnostic	group	
were	fitted	to	the	Rasch	model	separately,	and	then	the	pooled	data	from	each	diagnostic	group.	
Results	 The	 sample	 comprised	 3015	 patients,	 the	 majority,	 1996	 (66.2%)	 were	 women.	 Patient	
characteristics	 (stratified	 by	 diagnostic	 group)	 were	 comparable	 across	 countries	 except	 the	
educational	 background,	 which	 was	 variable.	 In	 most	 occasions,	 the	 39-item	 ENAT	 deviated	
significantly	 from	 the	 Rasch	model	 expectations	 (item-trait	 interaction	c2	p<0.05).	 After	 correction	
for	local	dependency	(grouping	the	items	into	seven	domains	and	analysing	them	as	"testlets"),	fit	to	
the	model	was	satisfied	(item-trait	interaction	c2	p>0.18)	in	all	pooled	disease	group	datasets	except	
OA	 (c2=99.91;	p=0.002).	 The	 internal	 consistency	 in	each	group	was	high	 (Person	Separation	 Index	
above	0.90).	There	was	no	significant	DIF	by	person	characteristics.	Cross-cultural	DIF	was	found	 in	
some	 items,	 which	 required	 adjustments.	 Subsequently,	 interval-level	 scales	 were	 calibrated,	 to	
enable	transformation	of	ENAT	scores	when	required.		






Patient	 education	 should	 be	 an	 integral	 part	 of	 the	management	 of	 rheumatic	 diseases.1-4	 It	 is	 an	
interactive	 process	 between	 patients	 and	 health	 care	 professionals	 aimed	 at	 enabling	 patients	 to	
participate	actively	in	their	health	care,	strengthen	their	ability	to	manage	symptoms	and	treatment,	
improve	coping	strategies	and	increase	self-care	abilities.5-7	It	is	important	for	health	professionals	to	




The	 educational	 needs	 assessment	 tool	 (ENAT)	 is	 a	 self-completed	 questionnaire,	 which	 allows	
patients	 with	 arthritis	 to	 prioritise	 their	 educational	 needs.	 If	 completed	 immediately	 before	 the	
consultation,	the	health	professional	is	able	to	provide	education	based	on	the	patient’s	immediate	
priorities.11	It	was	developed	by	people	with	arthritis	and	their	practitioners	in	the	UK,	and	comprises	
39	 items	 grouped	 into	 seven	 domains:	managing	 pain	 (six	 items),	movement	 (five	 items),	 feelings	
(four	items),	disease	process	(seven	items),	treatments	(seven	items),	self-help	measures	(six	items)	




validity	 and	 invariance	 to	 gender,	 age,	 disease	duration	 and	educational	 background.12	 In	 order	 to	
extend	 its	 use	 to	 European	 countries	 and	 allow	multinational	 comparison	 of	 educational	 needs	 of	
people	with	rheumatoid	arthritis	(RA),	the	ENAT	was	adapted	for	use	in	six	other	European	countries;	
(Finland,	 The	 Netherlands,	 Norway,	 Portugal,	 Spain	 and	 Sweden)	 and	 was	 found	 to	 have	 cross-




arthritis	 (PsA),	 systemic	 sclerosis	 (SSc),	 systemic	 lupus	erythematosus	 (SLE),	osteoarthritis	 (OA)	and	
fibromyalgia	syndrome	(FMS).14	The	aim	of	this	study	was	to	validate	the	ENAT	as	a	generic	tool	with	
which	 to	 assess	 the	 educational	 needs	 of	 patients	 with	 rheumatic	 diseases	 in	 seven	 European	
countries.	
Methods	 
Study design and patients 
This	 was	 a	 multicentre	 European	 collaborative	 study,	 funded	 by	 a	 research	 grant	 from	 European	
League	 Against	 Rheumatism	 (EULAR	 grant	 reference	 HPR011).	 It	 followed	 a	 cross-sectional	 survey	
design,	 requiring	 patient	 completion	 of	 the	 translated	 versions	 of	 the	 ENAT	 on	 one	 occasion	 and	
testing	its	cross-cultural	validity	using	Rasch	analysis.	The	study	was	led	from	the	University	of	Leeds	
(UK)	 and	 involved	 seven	 European	 countries;	 Austria,	 Finland,	 The	Netherlands,	Norway,	 Portugal,	




in-patient	wards,	databases,	 rehabilitation	centres	and/or	 from	the	community	 in	the	collaborating	
countries.	The	inclusion	criteria	were:	(i)	positive	diagnosis	of	the	target	diseases	(AS,	PsA,	SSc,	SLE,	




The	cross-cultural	adaptation	of	the	original	 (English)	ENAT	 into	the	respective	European	 languages	
was	previously	undertaken	in	RA,13	using	an	established	process	for	cross-cultural	adaptation	of	self-








"rheumatic	disease"	was	used	 for	all	diseases,	 including	OA.	This	 is	because	 in	 those	countries	 the	
term	"arthritis"	 implies	 the	presence	on	synovitis/effusion;	and	OA	 is	also	a	 rheumatic	disease	and	
recognised	by	patients	 and	health	 care	 professionals	 as	 such	 (albeit	 degenerative	 rather	 than	inflammatory).		
The	translated	versions	of	the	ENAT	were	given	to	patients	in	their	respective	countries	to	complete	
as	 postal	 surveys	 or	 before	 their	 clinic	 consultations	 or	 at	 the	 beginning	 of	 their	 rehabilitation	
programme.	 The	 ENATs	 were	 anonymous	 but	 contained	 patients’	 demographical	 data	 such	 as	
gender,	age,	educational	background	and	self-reported	disease	duration.	Once	completed,	the	ENATs	
were	sent	by	post	 to	 the	University	of	Leeds	 for	analysis.	The	ENAT	data	were	then	entered	 into	a	
database	 (IBM	 SPSS,	 version	 19)16	 and	 were	 subjected	 into	 Rasch	 analysis	 using	 RUMM202017	
software.	
Data analysis  
Rasch	 analysis	 is	 a	 mathematical	 modelling	 technique	 used	 to	 assess	 properties	 of	 outcome	
measures	against	a	measurement	model	developed	by	the	Danish	mathematician	Georg	Rasch.18	The	
Rasch	model	provides	a	formal	representation	of	 fundamental	measurement,	and	 in	Rasch	analysis	
the	observed	data	 from	questionnaires	 are	measured	 against	 the	Rasch	model	 to	 assess	 how	well	
they	 ’fit‘	 the	 model.	 Fit	 to	 the	 model	 implies	 a	 criterion-related	 construct	 validity,	 reliability	 and	
statistical	sufficiency.19-21	Further	details	of	Rasch	Analysis	tests	of	fit	are	published	elsewhere.22	





In	 the	analysis,	 the	 items	 that	were	 found	 to	be	 locally	dependent	 (a	correlation	of	±0.3	being	 the	
threshold	 for	 local	dependency)24	were	combined	 into	a	subtest	and	treated	as	a	 ’testlet‘,	which	 is	
defined	 as	 a	 subset	 of	 items	 that	 is	 treated	 as	 a	 measurement	 unit	 in	 test	 construction,	
administration	and/or	scoring.25		
The	data	from	each	diagnostic	group	from	each	country	were	tested	for	the	overall	fit	to	the	Rasch	
model	 and	 differential	 item	 functioning	 (DIF)	 by	 gender,	 age,	 disease	 duration	 and	 educational	
background.	 DIF	 occurs	 when	 two	 groups	 of	 equal	 ability	levels	 are	 not	 equally	 able	 to	 correctly	
answer	an	item.	If	the	factor	leading	to	DIF	is	not	part	of	the	construct	being	tested,	then	the	item	is	




medians.	 Educational	 background	 was	 simply	 categorised	 as:	 those	 with	 only	 compulsory	 (basic)	
education	and	those	with	further	education.	Group	comparisons	tested	the	assumption	of	invariance	
(absence	 of	 DIF)	 of	 the	 ENAT	 across	 all	 patient	 subgroups,	 that	 is	 	 age	 groups,	 gender,	 disease	
duration	 and	 educational	 background.	 Following	 country-specific	 analyses,	 the	 data	was	 pooled	 in	
each	 disease	 group	 and	 fit	 to	 the	 Rasch	 model	 was	 assessed.	 The	 pooled	 data	 were	 additionally	
tested	for	DIF	by	culture	(cross-cultural	bias).	Where	cross-cultural	DIF	was	found,	a	post-hoc	(Tukey	
test)	 was	 performed	 to	 assess	 where	 the	 significant	 difference	 lies,	 and	 the	 biased	 items	 were	
adjusted	for	the	using	the	method	described	by	Tennant	et	al29		and	Brodersen	et	al.28	
The	 overall	 fit	 statistics	 are	 reported	 as	 c2	 probability,	 where	 p-value	 is	 expected	 to	 be	 non-
significant	for	adequate	fit	to	the	model.	In	most	analyses,	the	p-values	were	Bonferroni-adjusted	to	
the	alevel	(ie,	p	=	0.05/number	of	tests	carried	out),	to	avoid	type	I	errors	due	to	multiple	testing.30	




Following	 fit	 to	 the	 Rasch	model,	 the	 test	 of	 strict	 unidimensionality	 of	 the	 ENAT	was	 conducted	
using	the	t-test	method	suggested	by	Smith,31	where	unidimensionality	is	confirmed	if	less	than	5%	of	
independent	t-tests	on	the	latent	estimates	derived	from	two	independent	sets	of	items	lie	outside	
the	 ±1.96	 range.	 The	 ENATs	 were	 then	 calibrated	 into	 an	 interval-level	 scale	 to	 allow	 for	 Rasch-
transformation	of	the	ordinal	data	into	interval	level	data	when	required.32	
Results  
A	 total	 of	 3219	 patients	 were	 recruited	 in	 this	 study.	 In	 all,	 74	 patients	 with	 undifferentiated	
spondyloarthropathy	from	Sweden	and	130	with	RA	from	Austria	were	excluded	from	the	analysis,	as	
these	diagnostic	groups	were	not	included	in	the	protocol.	This	meant	that	data	from	3015	patients	










	 Female	(%)	 Mean	(SD)	 Mean	(SD)	 Only	basic	
education	(%)	
AS	 PsA	 SSc	 SLE	 OA	 FMS	 Sample	
size	(N)	
Austria	 96	(55.8)	 55.3	(11.1)	 12.5	(10.6)	 86	(51.5)	 -	 125	 -	 -	 47	 -	 172	
Finland	 368	(82.1)	 53.2	(12.1)	 12.2	(10.3)	 115	(24.6)	 84	 86	 171	 -	 -	 108	 449	
The	
Netherlands	
368	(69.0)	 53.3	(15.1)	 13.8	(11.9)	 37	(6.7)	 85	 112	 103	 126	 126	 -	 552	
Norway	 398	(68.9)	 51.9	(12.0)	 10.6	(9.9)	 143	(24.4)	 146	 147	 -	 -	 149	 144	 586	
Portugal	 362	(64.0)	 50.8	(15.3)	 13.0	(10.1)	 228	(42.1)	 121	 132	 28	 146	 88	 53	 568	
Spain	 321	(63.8)	 48.2	(13.8)	 12.6	(9.8)	 180	(37.0)	 141	 124	 59	 99	 23	 57	 503	
Sweden	 83	(44.9)	 55.8	(12.5)	 21.0	(12.1)	 55	(29.7)	 102	 83	 -	 -	 -	 -	 185	









Lack	 of	 fit	 to	 the	 model	 was	 caused	 by	 significant	 correlations	 of	 items	 within	 each	 domains	 (a	













Residual	 Chi	Square	Interaction	 	 	 Proportion	of	
significant	(95%	CI)		 	 Analysis	 Mean	 SD	 Mean	 SD	 Value	(df)	 p	 PSI	 N	
Norway	 AS
	 Analysis	1	 0.315	 1.643	 -0.238	 1.186	 163.045	(78)	 0.001	 0.97	 142	 	
Analysis	2	 0.189	 0.87	 -0.322	 1.131	 12.005	(14)	 0.606	 0.947	 142	 0.085	(0.049,	0.120)	
Finland	 AS
	 Analysis	1	 0.418	 1.197	 -0.214	 2.136	 38.262	(39)	 0.503	 0.969	 85	 	
Analysis	2	 0.421	 0.612	 -0.237	 1.102	 8.780	(7)	 0.269	 0.927	 85	 0.094	(0.048,	0.140)	
Sweden	 AS
	 Analysis	1	 0.379	 0.991	 -0.25	 2.136	 121.031	(78)	 0.001	 0.901	 102	 	
Analysis	2	 0.38	 0.624	 -0.277	 1.19	 6.818	(7)	 0.448	 0.623	 102	 0.040	(-0.003,	0.082)	
The	
Netherlands	 A
S	 Analysis	1	 0.355	 1.362	 -0.261	 2.208	 50.328	(39)	 0.106	 0.978	 82	 	
Analysis	2	 0.481	 0.998	 -0.25	 1.167	 4.281	(7)	 0.747	 0.947	 82	 0.123	(0.076,	0.171)	
Portugal	 AS
	 Analysis	1	 0.421	 1.353	 -0.662	 2.946	 54.546	(39)	 0.502	 0.966	 121	 	
Analysis	2	 0.372	 0.291	 -0.364	 1.205	 6.021	(7)	 0.537	 0.902	 121	 0.057	(0.019,	0.097)	
Spain	 AS
	 Analysis	1	 0.277	 1.947	 -0.289	 2.199	 184.606	(78)	 0.001	 0.976	 129	 	
Analysis	2	 0.301	 1.116	 -0.345	 1.175	 12.970	(14)	 0.529	 0.953	 128	 0.070	(0.033,	0.108)	
Austria		 Ps
A	 Analysis	1	 0.286	 1.147	 -0.382	 2.041	 97.313	(78)	 0.068	 0.967	 123	 	
Analysis	2	 0.611	 1.021	 -0.363	 1.284	 11.541	(14)	 0.643	 0.931	 119	 0.076	(0.036,	0.115)	
Norway	 Ps
A	 Analysis	1	 0.379	 1.258	 -0.08	 1.671	 156.851	(78)	 <0.001	 0.969	 142	 	
Analysis	2	 0.442	 0.654	 -0.237	 1.023	 10.012	(14)	 0.761	 0.933	 142	 0.056	(0.021,	0.093)	
Finland	 Ps
A	 Analysis	1	 0.297	 1.121	 -0.159	 2.032	 55.614	(39)		 0.041	 0.977	 82	 	
Analysis	2	 0.138	 0.88	 -0.256	 1.041	 6.044	(7)	 0.535	 0.954	 82	 0.061	(0.014,	0.108)	
Sweden	 Ps
A	 Analysis	1	 0.432	 1.003	 -0.269	 2.169	 51.271	(39)	 0.09	 0.96	 82	 	
Analysis	2	 0.519	 0.617	 -0.39	 1.281	 10.698	(7)	 0.152	 0.91	 82	 0.074	(0.027,	0.122)	
The	 Ps
A	 Analysis	1	 0.609	 1.708	 -0.233	 2.301	 77.078	(39)	 <0.001	 0.974	 110	 	
 9 
Netherlands	 Analysis	2	 0.805	 1.316	 -0.255	 1.181	 6.117	(7)	 0.526	 0.936	 108	 0.093	(0.051,	0.134)	
Portugal	 Ps
A	 Analysis	1	 0.379	 1.862	 -0.679	 2.986	 162.025	(78)	 <0.001	 0.983	 126	 	
Analysis	2	 0.438	 1.119	 -0.499	 1.357	 12.743	(14)		 0.547	 0.959	 126	 0.065	(0.026,	0.103)	
Spain	 Ps
A	 Analysis	1	 0.544	 1.761	 -0.169	 2.166	 90.500	(39)	 <0.001	 0.974	 115	 	
Analysis	2	 0.44	 1.154	 -0.301	 1.125	 5.473	(7)	 0.602	 0.954	 114	 0.070	(0.030,	0110)	
Finland	 SS
c	 Analysis	1	 0.532	 1.596	 -0.476	 2.613	 126.607	(78)	 <0.001	 0.969	 167	 	




	 Analysis	1	 0.453	 1.59	 -0.188	 2.154	 89.627	(39)	 <0.001	 0.978	 99	 	
Analysis	2	 0.836	 0.745	 -0.248	 1.248	 6.862	(7)	 0.443	 0.951	 99	 0.040	(-0.003,	0.083)	
Portugal	 SS
c	 Analysis	1	 0.38	 0.798	 0.055	 1.999	 22.310	(39)	 0.985	 0.977	 28	 	
Analysis	2	 0.645	 0.529	 -0.011	 0.975	 3.037	(7)	 0.882	 0.938	 28	 0.107	(0.026,	0.188)	
Spain	 SS
c	 Analysis	1	 0.291	 1.146	 -0.052	 1.748	 52.626	(39)	 0.071	 0.98	 39	 	




	 Analysis	1	 0.511	 1.818	 -0.329	 2.626	 112.920	(39)	 <0.001	 0.970	 123	 	
Analysis	2	 0.397	 1.176	 -0.346	 1.244	 5.862	(7)	 0.556	 0.939	 123	 0.059	(0.020,	0.098)	
Portugal	 SL
E	 Analysis	1	 0.182	 1.264	 -0.426	 2.405	 164.349	(78)	 <0.001	 0.973	 142	 	
Analysis	2	 0.416	 0.957	 -0.423	 1.317	 11.591	(14)	 0.639	 0.936	 142	 0.049	(0.013,	0.085)	
Spain	 SL
E	 Analysis	1	 0.508	 1.542	 -0.020	 1.700	 104.037	(39)	 <0.001	 0.964	 95	 	
Analysis	2	 0.494	 0.651	 -0.233	 1.053	 19.581	 0.144	 0.933	 95	 0.055	(0.010,	0.100)	
Finland	 FM
S	 Analysis	1	 0.262	 1.401	 -0.192	 1.824	 57.954	(39)	 0.026	 0.969	 105	 	
Analysis	2	 0.324	 0.879	 -0.171	 0.953	 3.438	(7)	 0.842	 0.936	 105	 0.059	(0.017,	0.101)	
Norway	 FM
S	 Analysis	1	 0.267	 1.612	 -0.107	 1.529	 126.819	(78)	 <0.001	 0.96	 133	 	
Analysis	2	 0.222	 0.736	 -0.257	 1.009	 12.144	(14)	 0.595	 0.928	 133	 0.045	(0.008,	0.082)	
Portugal	 FM
S	 Analysis	1	 0.527	 0.725	 -0.227	 2.635	 73.211	(39)	 <0.001	 0.99	 41	 	
Analysis	2	 0.687	 0.589	 -0.128	 1.201	 7.339	(7)	 0.394	 0.984	 41	 0.073	(0.006,	0.140)	
Spain	 FM
S	 Analysis	1	 0.388	 1.518	 0.166	 1.548	 120.972	(39)	 <0.001	 0.971	 50	 	
Analysis	2	 0.195	 0.640	 -0.105	 0.706	 8.157	(7)	 0.319	 0.946	 50	 0.040	(-0.020,	0.100)	
Austria	OA	 O
A	 Analysis	1	 0.147	 0.827	 -0.122	 1.794	 61.360	(39)	 0.013	 0.951	 47	 	
Analysis	2	 0.55	 1.136	 -0.224	 1.141	 12.759	(7)	 0.078	 0.886	 47	 0.085	(0.023,	0147)	
The	
Netherlands		 O
A	 Analysis	1	 0.431	 1.497	 -0.257	 2.42	 333.770	(273)	 0.007	 0.976	 121	 	
Analysis	2	 0.294	 0.784	 -0.284	 1.154	 5.692	(7)	 0.576	 0.947	 121	 0.041	(0.003,	0.081)	
Norway	 O
A	 Analysis	1	 0.227	 1.489	 -0.255	 1.72	 113.076	(78)	 0.006	 0.97	 138	 	
Analysis	2	 0.395	 0.811	 -0.296	 1.103	 16.310	(14)	 0.295	 0.947	 138	 0.044	(0.007,	0.081)	
Portugal		 O
A	
Analysis	1	 -0.427	 1.832	 -1.885	 3.593	 78.487	(39)	 <0.001	 0.992	 77	 	
Analysis	2	 0.493		 1.710		 -0.452		 1.350		 14.765	(7)		 0.039		 0.987		 77	 0.064	(0.016,	0.114)	
Spain	 O
A	 Analysis	1	 0.284	 0.8	 0.143	 2.329	 70.762	 0.001	 0.95	 23	 	
Analysis	2	 0.272	 0.543	 -0.121	 0.967	 7.426	(7)	 0.386	 0.89	 23	 0.130	(0.041,	0.220)	
Expected	values	for	a	perfect	










indicating	 an	 excellent	 reliability	 (internal	 consistency)	 for	 both	 group	 and	 individual	 uses.	 Strict	
unidimensionality	of	the	overall	scale	was	confirmed	in	all	disease	groups	except	 in	the	AS	and	PsA	
diagnostic	 groups	 in	which	 the	proportions	 of	 significant	 t-tests	 (95%CI)	were	 0.074	 (0.058,	 0.092)	













(95%	CI)			 Analysis	 Mean	 SD	 Mean	 SD	 Value	(df)	 p	 N	
Pooled	
AS	
Analysis	1	 0.563	 2.959	 -0.557	 2.584	 683.931	(351)	 <0.001	 0.972	 661	 		





Analysis	1	 0.957	 3.096	 -0.499	 2.517	 787.691	(351)	 <0.001	 0.975	 780	 		





Analysis	1	 0.699	 2.232	 -0.532	 2.634	 527.415	(351)	 <0.001	 0.976	 333	 		





Analysis	1	 0.560	 2.559	 -0.497	 2.551	 476.407	(234)	 <0.001	 0.969	 360	 		





Analysis	1	 0.607	 2.482	 -0.251	 1.972	 450.441	(273)	 <0.001	 0.972	 329	 		





Analysis	1	 0.775	 2.689	 -0.701	 3.022	 709.905	(351)	 <0.001	 0.976	 430	 	
Analysis	2	 0.406	 1.845	 -0.434	 1.273	 99.906	(63)	 0.002	 0.950	 429	 Misfit	
Expected	values	for	a	








A	 formal	 assessment	 of	 invariance	 (DIF	 analysis)	 was	 performed	 in	 the	 diagnostic	 groups	 that	
satisfied	the	Rasch	model	requirements	(AS,	PsA,	SSc,	SLE	and	FMS).	There	was	no	significant	DIF	by	





	 AS	 PsA	 SSc	 SLE	 FMS	
Pain	 X	 X	 S	 S	 S	
Movements	 S	 S	 S	 X	 S	
Feelings	 S	 S	 S	 S	 S	
Disease	process	 S	 X	 S	 S	 S	
Treatments	 S	 X	 X		 X		 S	
Self-help	 S	 X	 S	 S	 S	










the	 ENAT	 can	 be	 used	 in	 its	 present	 form	within	 each	 country	without	 any	 need	 for	 adjustments.	
However,	 when	 data	 across	 countries	 are	 being	 pooled	 or	 compared,	 then	 adjustment	 for	 cross-





Domain	 Testlet	 Location	 SE	 Fit	Residuals	 X
2	 P	
AS	 	 	 	 	 	 	
Pain	 Pain-Norway	 -0.15	 0.03	 -1.13	 7.76	 0.56	
Pain-	Others	 -0.01	 0.01	 0.47	 14.70	 0.10	
Movement	 Movement	 0.07	 0.01	 -0.80	 10.73	 0.29	
Feelings	 Feelings	 0.04	 0.01	 -0.18	 16.08	 0.07	
Disease	process	 Disease	process	 -0.14	 0.01	 0.21	 8.11	 0.52	
Treatments	 Treatments	 0.04	 0.01	 0.83	 7.97	 0.54	
Self-Help	 Self-Help	 -0.10	 0.01	 2.04	 5.59	 0.78	
Support	 Support	–The	Netherlands	 0.15	 0.04	 -0.96	 7.18	 0.62	
Support	-	Others	 0.09	 0.01	 0.70	 10.02	 0.35	
PsA	 	 	 	 	 	 	
Pain	 Pain	-	Austria	 -0.06	 0.03	 -1.07	 6.73	 0.46	
Pain	-	Norway	 -0.70	 0.04	 0.23	 6.54	 0.48	
Pain	–	The	Netherlands	 0.13	 0.03	 -0.09	 5.69	 0.58	
	 Pain	-	Others	 0.08	 0.02	 -0.57	 5.65	 0.58	
Movement	 Movement	 0.20	 0.01	 2.51	 8.28	 0.31	
Feelings	 Feelings	 0.16	 0.01	 2.45	 4.09	 0.77	
Disease	process	 Disease	process	-	Finland	 -0.15	 0.04	 -1.93	 4.71	 0.70	
Disease	process	-	Others	 -0.13	 0.01	 -0.11	 4.99	 0.66	
Treatments	 Treatments	-	The	Netherlands	 -0.08	 0.03	 0.77	 8.07	 0.33	
Treatments-	Sweden	 -0.05	 0.03	 1.35	 5.09	 0.65	
	 Treatments	-	Others	 0.14	 0.01	 -0.27	 7.72	 0.36	
Self-Help	 Self-Help	-	The	Netherlands	 -0.22	 0.03	 2.54	 17.90	 0.01	
Self-Help	-	Portugal	 0.16	 0.03	 0.38	 3.55	 0.83	
Self-Help	-	Others	 -0.05	 0.01	 0.37	 9.73	 0.20	
Support	 Support	-	Austria	 0.49	 0.03	 1.37	 4.74	 0.69	
Support-	Finland	 -0.40	 0.05	 -0.93	 6.53	 0.48	
Support	-	Portugal	 0.21	 0.03	 0.87	 5.68	 0.58	
	 Support	-	Others	 0.25	 0.02	 0.44	 8.69	 0.28	
SSc	 	 	 	 	 	 	
Pain	 Pain	 0.06	 0.02	 0.17	 6.93	 0.23	
Movements	 Movements	 0.12	 0.02	 -0.99	 8.34	 0.14	
Feelings	 Feelings	 0.09	 0.02	 1.79	 3.37	 0.64	
Disease	process	 Disease	process	 -0.21	 0.02	 -0.02	 10.97	 0.05	
Treatments	 Treatments-	The	Netherlands	 -0.06	 0.03	 1.96	 3.50	 0.62	
Treatments-Others	 0.03	 0.02	 0.74	 5.61	 0.35	
Self-Help	 Self-Help	 -0.16	 0.02	 0.77	 4.13	 0.53	
Support	 Support	-	The	Netherlands	 0.22	 0.04	 1.23	 3.62	 0.61	
Support	-	Others	 -0.09	 0.03	 1.28	 10.51	 0.06	
SLE	 	 	 	 	 	 	
Pain	 Pain	 0.01	 0.02	 -0.13	 5.31	 0.50	
Movement	 Movements-Spain	 0.03	 0.03	 -0.43	 4.41	 0.62	
Movements	-	Others	 0.06	 0.02	 0.05	 2.28	 0.89	
Feelings	 Feelings	 -0.04	 0.02	 2.16	 5.56	 0.47	
Disease	process	 Disease	process	 -0.18	 0.01	 -0.60	 12.62	 0.05	
Treatments	 Treatments	-	Spain	 0.18	 0.02	 0.27	 4.02	 0.67	
Treatments	-	Others	 -0.02	 0.02	 0.75	 4.23	 0.65	
Self-Help	 Self-Help	 -0.12	 0.02	 0.18	 6.20	 0.40	
Support	 Support	 0.08	 0.02	 2.05	 9.22	 0.16	
FMS	 	 	 	 	 	 	
Pain	 Pain	 -0.04	 0.02	 0.40	 5.38	 0.37	
Movements	 Movements	 -0.04	 0.02	 0.68	 3.56	 0.61	
Feelings	 Feelings	 -0.05	 0.02	 0.79	 3.20	 0.67	
Disease	process	 Disease	process	 -0.13	 0.02	 -1.24	 6.88	 0.23	
Treatments	 Treatments	 0.28	 0.02	 1.96	 5.52	 0.36	
Self-Help	 Self-Help	 -0.08	 0.02	 0.13	 8.72	 0.12	
Support	 Support	-	The	Netherlands	 0.06	 0.02	 -0.14	 6.12	 0.29	
SE	=	Standard	error,	P	=	Bonferroni-adjusted	Χ2	probability,	(non-significant	P	=	Fit	to	the	model),	
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Following	adjustment	 to	 the	 cross-cultural	DIF	 (in	 the	AS,	 PsA,	 SSc	 and	SLE	diagnostic	 groups),	 the	
raw	ENAT	domain	scores	were	mapped	against	the	corresponding	Rasch-transformed	scores	(based	
in	 logits)	 and	were	 linearly	 transformed	 to	 calibrate	 interval-level,	DIF-adjusted	 scales	of	 the	 same	




needs	 in	 people	 with	 AS,	 PsA,	 SSc,	 SLE,	 OA	 and	 FMS	 in	 different	 European	 countries.	 The	 results	
indicate	 that,	 following	 its	 adaptation;	 the	 ENAT	maintained	 its	 validity	 in	 each	disease	 group	 that	
was	 tested	 (with	 limitations	 in	 OA).	 The	 implications	 of	 the	 results	 in	 terms	 of	 clinical	 use	 and	
measurement	aspects	are	set	out	below.		
In	 the	 clinical	 practice,	 the	 ENAT	 is	 used	 as	 a	 template/checklist	 to	 assess	 what	 are	 the	 most	
important	educational/informational	needs	from	the	patient’s	point	of	view.	Patients	using	the	ENAT	
have	 consistently	 found	 it	 easy	 to	 complete	 and	 effective	 in	 identifying	 their	 needs	 and	 raise	
questions	 which	 they	 would	 not	 have	 otherwise	 considered.12,33	 This	 information,	 along	 with	 the	
clinicians’	 insight	of	what	the	patient	needs	to	know,	allows	the	provision	of	timely	and	meaningful	
education	 tailored	 to	 the	 needs	 of	 each	 individual	 patient.	 When	 used	 in	 this	 way	 (for	 clinical	




requirement	 for	questionnaires	with	 items	 that	 are	 intended	 to	be	 summed	 together	 to	provide	a	
total	 score.22	While	 the	 level	of	 ‘educational	needs’	 represented	by	each	domain	may	differ	across	
disease	groups,	 fit	 to	the	Rasch	model	confirms	the	validity	of	the	 ‘educational	needs’	construct	as	
measured	 by	 the	 ENAT	 in	 each	 disease	 group	 (with	 limitations	 in	 OA).	 Local	 dependency	was	 the	
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main	 issue	affecting	measurement	properties	of	 the	ENAT.	Since	 the	 items	within	a	domain	are	by	




measurement	 requirements	 of	 the	 scale.	 This	 approach	 to	 scoring	 is	 similar	 to	 that	 used	 in	 other	
scales	such	as	the	HAQ34	and	the	HADs.35	
While	 the	 ENAT	 was	 invariant	 to	 person	 characteristics,	 some	 items	 worked	 differently	 in	 some	
countries	 especially	 in	 the	OA	 and	 SpA	 disease	 groups.	 Therefore,	when	 the	 data	 across	 different	
countries	are	combined/compared,	adjustments	will	be	required	(cross-cultural	comparisons	are	not	
possible	 in	 OA).	 We	 have	 calibrated	 interval-level	 scales	 (see	 online	 supplementary	 tables	 1-14),	
which	are	adjusted	to	cross-cultural	DIF,	thus	enabling	accurate	estimation	of	educational	needs	and	
comparison	across	the	countries	when	required.	Previous	estimation	of	educational	needs	for	people	
with	 arthritis	 used	 the	 ENAT	 ordinal	 measures	 and	 non-parametric	 methods,33,36	 which	 can	 be	
limiting	 if	other	outcome	measures	have	 to	be	 taken	 into	account	 in	 the	analyses	such	as	 in	 linear	
regression	 models.	 Conversion	 of	 the	 ordinal	 measures	 into	 interval	 levels	 (Rasch-transformed	
values)	 enables	 the	 use	 of	 ENAT	 scores	 in	 parametric	 analyses,32	 alongside	 other	measures,	 given	
adequate	sample	sizes	and	normal	distribution.	Recently,	Rasch-transformed	scores	 from	the	ENAT	
have	been	used	to	assess	to	its	correlation	with	disease	activity	and	disability	in	RA	and	PsA.37		













change	has	not	been	established.	However,	 given	 the	nature	of	needs	assessment,	 it	 is	difficult	 to	
establish	 ‘stability’	 as	 the	 educational	 needs	 are	 dynamic.	 Lastly,	 due	 to	 developments	 in	 the	
understanding	 of	 rheumatic	 diseases	 and	 their	 management,	 coupled	 by	 developments	 in	
information	technology,	the	ENAT	 items	do	not	cover	everything	there	 is	to	know	about	rheumatic	












checklist	 does	 not	 require	 scoring,	 its	 interval-level	 scale	 provides	 estimates	 that	 can	 be	 used	
alongside	other	variables	 in	parametric	analyses.	 In	addition,	a	 facility	 is	available	 for	cross-cultural	
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